Stryker proposes a takeover bid for Boston Scientific Corporation
Category: #health  By Dhananjay Punekar  Date: 2018-06-12
  • share
  • Twitter
  • Facebook
  • LinkedIn

Stryker proposes a takeover bid for Boston Scientific Corporation

Stryker Corporation, a Fortune 500 medical tech firm, has reportedly announced that it plans to acquire Boston Scientific Corporation, a U.S. based medical device manufacturer. Incidentally, both the firms boast of a considerable number of operations in Ireland.

For the record, Stryker alone encompasses a workforce of 2,000 at four sites in Ireland – one at Limerick and three at Cork. Boston Scientific, reputed for the production of pacemakers & stents, has over 3,000 staff working for the company in Ireland, that houses three of Boston’s five European facilities.

According to Bloomberg, the market value of Boston Scientific Corp. has been estimated at approximately USD 50 billion, while Stryker Corp. is currently evaluated at USD 65 billion. Boston Scientific is facing tough competition from Edward Lifesciences Corp. and Medtronic plc across the medical devices market. However, the firm is likely to introduce the new version of its Lotus device in the market next year. Last year, it had withdrawn the earlier version of the device from Europe medical device market.  

The deal between the two medical device manufacturers is likely to be the latest among the acquisition wave witnessed across the healthcare sector. As per authentic reports, last year, Abbot Laboratories, a U.S. based healthcare firm, acquired St. Jude Medical Inc., an American medical device firm, for USD 25 billion. Later, during the same year, Abbot Laboratories purchased Alere Inc., medical testing & diagnostics supplier for USD 5 billion. In yet another acquisition move witnessed across healthcare, Medtronic purchased Covidien for approximately USD 46 billion in 2015.

While Stryker Corp has already initiated a takeover approach, it is still doubtful whether Boston Scientific Corp. would be receptive to the same, cite reports. However, analysts speculate that the merger between both these medical magnates may increase their overall worth while helping them sell their products across a common consumer base.



About Author

Dhananjay Punekar

Email: [email protected]   

Dhananjay Punekar

Dhananjay Punekar presently develops content for a slew of portals, including Market Size Forecasters and Algosonline. A post graduate in mathematics and business administration, he worked in Infosys BPO Limited prior to switching his professional genre. As a content wr...

Read More

More News By Dhananjay Punekar

AstraZeneca gets import & marketing approval for Durvalumab in India
AstraZeneca gets import & marketing approval for Durvalumab in India
By Dhananjay Punekar

AstraZeneca Pharma India, a division of pharma & biopharma giant AstraZeneca plc, has received a green signal from the Indian drug regulating agency DCGI (Drug Controller General of India) for its drug Durvalumab c...

BP exits deal with Woolworths, retail firm looks out for alternatives
BP exits deal with Woolworths, retail firm looks out for alternatives
By Dhananjay Punekar

BP Plc, a UK based oil & gas firm, has decided to terminate its USD 1.8 billion acquisition deal with Australian retail giant Woolworths. For the record, the British oil & gas company had signed a pact to purch...

Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
By Dhananjay Punekar

The shares of Sarepta Therapeutics Inc., a medical research & drug development firm, climbed up by 50% after the firm released initial results derived from clinical treatment on patients suffering from Duchenne mus...